John Mignone, MD
Advanced Heart Failure and Transplant Cardiology · Seattle, WANPI 1194834127
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Boehringer Ingelheim at 41.2% of the total. Reporting peaked in 2023 at $8,218 and has fallen 98.1% since, to $159 in 2025.
Across 79 payments — averaging $235.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- Medtronic$7K
- Abbott$1K
- Lilly USA, LLC$1K
- Impulse Dynamics (USA) Inc.$294
- Abiomed$289
- plus $738 from 9 others
Across 76 payments — averaging $6958.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$296K
- Abbott$80K
- Impulse Dynamics (USA) Inc.$63K
- Medtronic$41K
- Amgen$39K
- American Regent$10K
What the payments were for
- Consulting fees$4,00022%
- Speaking & faculty fees$10,65057%
- Travel & lodging$8334%
- Food & beverage$3,09917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $7,654 |
| Medtronic(2 entities) | 16 | $7,080 |
| Abbott | 38 | $1,475 |
| Lilly USA, LLC | 2 | $1,050 |
| Impulse Dynamics (USA) Inc. | 3 | $294 |
| Abiomed | 5 | $289 |
| Cvrx, Inc. | 2 | $262 |
| Janssen Scientific Affairs, LLC | 1 | $153 |
| Boston Scientific | 1 | $99 |
| Edwards Lifesciences | 1 | $63 |
| Catheter Precision Inc. | 1 | $50 |
| Atricure, Inc. | 1 | $48 |
| Novartis | 1 | $24 |
| AbbVie | 1 | $23 |
| Sensible Medical Innovations Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$8,657
- OPTIMIZER$542
- Barostim Neo System$262
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$251
- HeartMate 3 Left Ventricular Dev$156
- XARELTO$153
- AVEIR$126
- Impella$125
- COBALT DR MRI SURESCAN$110
How this compares
$18,581 in reported general payments places this provider in the 75th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.
See all advanced heart failure and transplant cardiology providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 61 | $1,546,413 |
| EntrestoSacubitril/Valsartan | 72 | $106,376 |
| EliquisApixaban | 36 | $54,126 |
| JardianceEmpagliflozin | 56 | $52,843 |
| FarxigaDapagliflozin Propanediol | 34 | $39,798 |
| Metoprolol Succinate | 120 | $1,633 |
| Rosuvastatin Calcium | 31 | $1,582 |
| Losartan Potassium | 52 | $1,169 |
| Carvedilol | 43 | $1,050 |
| Candesartan Cilexetil | 18 | $1,023 |
| Eplerenone | 16 | $828 |
| Amlodipine Besylate | 14 | $777 |
| Torsemide | 35 | $749 |
| Bisoprolol Fumarate | 27 | $547 |
| Spironolactone | 56 | $448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $24 | $106,37672 claims |
| Boehringer IngelheimJardiance | $7,654 | $52,84356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.
Other advanced heart failure and transplant cardiology in Seattle
- Wayne LevySeattle$275K
- Preethi PirlamarlaSeattle$14K
- Salpy PamboukianSeattle$5K
- James ZhangSeattle$3K
- April Stempien OteroSeattle$2K
- Sunu ThomasSeattle$2K
- Richard ChengSeattle$759
- Elina MinamiSeattle$698
- Daniel FishbeinSeattle$600
- Kevin ObrienSeattle$222
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.